S&P 500   4,966.64 (-0.18%)
DOW   38,527.79 (-0.09%)
QQQ   423.59 (-0.87%)
AAPL   181.31 (-0.14%)
MSFT   399.10 (-0.92%)
META   467.11 (-0.88%)
GOOGL   142.14 (+0.72%)
AMZN   168.21 (+0.68%)
TSLA   193.97 (+0.11%)
NVDA   670.52 (-3.46%)
NIO   6.05 (+1.51%)
AMD   163.37 (-1.40%)
BABA   75.68 (+3.47%)
T   16.97 (+0.35%)
F   12.13 (-0.98%)
MU   80.59 (-0.15%)
CGC   3.42 (-3.39%)
GE   148.19 (-0.29%)
DIS   107.71 (-1.58%)
AMC   4.56 (-2.15%)
PFE   27.50 (-0.33%)
PYPL   57.59 (-1.77%)
XOM   104.75 (+1.95%)
S&P 500   4,966.64 (-0.18%)
DOW   38,527.79 (-0.09%)
QQQ   423.59 (-0.87%)
AAPL   181.31 (-0.14%)
MSFT   399.10 (-0.92%)
META   467.11 (-0.88%)
GOOGL   142.14 (+0.72%)
AMZN   168.21 (+0.68%)
TSLA   193.97 (+0.11%)
NVDA   670.52 (-3.46%)
NIO   6.05 (+1.51%)
AMD   163.37 (-1.40%)
BABA   75.68 (+3.47%)
T   16.97 (+0.35%)
F   12.13 (-0.98%)
MU   80.59 (-0.15%)
CGC   3.42 (-3.39%)
GE   148.19 (-0.29%)
DIS   107.71 (-1.58%)
AMC   4.56 (-2.15%)
PFE   27.50 (-0.33%)
PYPL   57.59 (-1.77%)
XOM   104.75 (+1.95%)
S&P 500   4,966.64 (-0.18%)
DOW   38,527.79 (-0.09%)
QQQ   423.59 (-0.87%)
AAPL   181.31 (-0.14%)
MSFT   399.10 (-0.92%)
META   467.11 (-0.88%)
GOOGL   142.14 (+0.72%)
AMZN   168.21 (+0.68%)
TSLA   193.97 (+0.11%)
NVDA   670.52 (-3.46%)
NIO   6.05 (+1.51%)
AMD   163.37 (-1.40%)
BABA   75.68 (+3.47%)
T   16.97 (+0.35%)
F   12.13 (-0.98%)
MU   80.59 (-0.15%)
CGC   3.42 (-3.39%)
GE   148.19 (-0.29%)
DIS   107.71 (-1.58%)
AMC   4.56 (-2.15%)
PFE   27.50 (-0.33%)
PYPL   57.59 (-1.77%)
XOM   104.75 (+1.95%)
S&P 500   4,966.64 (-0.18%)
DOW   38,527.79 (-0.09%)
QQQ   423.59 (-0.87%)
AAPL   181.31 (-0.14%)
MSFT   399.10 (-0.92%)
META   467.11 (-0.88%)
GOOGL   142.14 (+0.72%)
AMZN   168.21 (+0.68%)
TSLA   193.97 (+0.11%)
NVDA   670.52 (-3.46%)
NIO   6.05 (+1.51%)
AMD   163.37 (-1.40%)
BABA   75.68 (+3.47%)
T   16.97 (+0.35%)
F   12.13 (-0.98%)
MU   80.59 (-0.15%)
CGC   3.42 (-3.39%)
GE   148.19 (-0.29%)
DIS   107.71 (-1.58%)
AMC   4.56 (-2.15%)
PFE   27.50 (-0.33%)
PYPL   57.59 (-1.77%)
XOM   104.75 (+1.95%)

Embecta (EMBC) Stock Price, News & Analysis

$14.65
+0.35 (+2.45%)
(As of 01:57 PM ET)
Today's Range
$14.12
$14.66
50-Day Range
$14.25
$19.33
52-Week Range
$12.72
$33.07
Volume
121,044 shs
Average Volume
430,637 shs
Market Capitalization
$843.55 million
P/E Ratio
15.42
Dividend Yield
4.10%
Price Target
$16.00

Embecta MarketRank™ Stock Analysis

Analyst Rating
Reduce
1.50 Rating Score
Upside/​Downside
9.2% Upside
$16.00 Price Target
Short Interest
Healthy
4.21% of Float Sold Short
Dividend Strength
Strong
Based on Four Factors
Sustainability
N/A
News Sentiment
1.82mentions of Embecta in the last 14 days
Based on 3 Articles This Week
Insider Trading
Acquiring Shares
$32,500 Bought Last Quarter
Proj. Earnings Growth
3.27%
From $2.14 to $2.21 Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

3.00 out of 5 stars

Medical Sector

246th out of 932 stocks

Surgical & Medical Instruments Industry

31st out of 95 stocks


EMBC stock logo

About Embecta Stock (NASDAQ:EMBC)

Embecta Corp., a medical device company, focuses on the provision of various solutions to enhance the health and wellbeing of people living with diabetes. Its products include pen needles, syringes, and safety injection devices, as well as digital applications to assist people with managing patient's diabetes. The company primarily sells its products to wholesalers and distributors in the United States and internationally. Embecta Corp. was founded in 1924 and is headquartered in Parsippany, New Jersey.

EMBC Stock Price History

EMBC Stock News Headlines

Embecta (NASDAQ:EMBC) Has Affirmed Its Dividend Of $0.15
An Unusual Way to Invest in Gold
Most financial experts recommend including gold in your investment mix to protect against rising prices and keep wealth secure. Investors are discovering a little-known way to benefit from gold, which offers the chance to gain from higher gold prices and mining successes while avoiding the costs of operating mines.
Embecta Shareholders Approve Directors and Compensation Plans
Embecta Shares Fall Despite Outlook Raise, Strong 1Q
Americans Now Favor Gold Over Stocks as an Investment Vehicle
Americans now consider gold a better long-term investment than stocks for the first time since 2013. But physical gold requires storage and insurance, and gold mining stocks come with significant risks. Fortunately, investors have found a little-known way to benefit from gold that avoids many of these challenges.
Embecta Sinks As Outlook Comes In Below Consensus
Why Embecta Stock Is Tanking Today
Earnings Preview For Embecta
Embecta Corp's Dividend Analysis
Embecta: Q4 Earnings Insights
See More Headlines
Receive EMBC Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Embecta and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Ex-Dividend for 12/15 Dividend
12/01/2023
Dividend Payable
12/15/2023
Last Earnings
2/09/2024
Today
2/21/2024
Ex-Dividend for 3/15 Dividend
2/27/2024
Dividend Payable
3/15/2024
Next Earnings (Estimated)
5/10/2024
Fiscal Year End
9/30/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Surgical & medical instruments
Sub-Industry
N/A
Current Symbol
NASDAQ:EMBC
Fax
N/A
Employees
2,200
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$16.00
High Stock Price Target
$16.00
Low Stock Price Target
$16.00
Potential Upside/Downside
+11.9%
Consensus Rating
Reduce
Rating Score (0-4)
1.50
Research Coverage
2 Analysts

Profitability

Net Income
$70.40 million
Pretax Margin
5.69%

Debt

Sales & Book Value

Annual Sales
$1.12 billion
Cash Flow
$3.65 per share
Book Value
($13.78) per share

Miscellaneous

Free Float
57,418,000
Market Cap
$823.39 million
Optionable
Optionable
Beta
0.86
The Best High-Yield Dividend Stocks for 2024 Cover

Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.

Get This Free Report

Key Executives

  • Mr. Devdatt Kurdikar (Age 56)
    President, CEO & Director
    Comp: $2.2M
  • Mr. Jacob P. Elguicze (Age 51)
    Senior VP & CFO
    Comp: $1.05M
  • Mr. Brian R. Capone (Age 49)
    VP, Chief Accounting Officer & Corporate Controller
    Comp: $645.16k
  • Mr. Jeffrey Z. Mann (Age 52)
    Senior VP, General Counsel, Head of Business Development & Corporate Secretary
    Comp: $959.45k
  • Mr. Shaun Curtis (Age 55)
    Senior Vice President of Global Manufacturing & Supply Chain
    Comp: $915.67k
  • Ms. Colleen Riley (Age 60)
    Senior VP & Chief Technology Officer
  • Mr. Pravesh Khandelwal
    VP & Head of Investor Relations
  • Ms. Ginny Blocki
    Senior Vice President of Global Marketing & Product Management
  • Ms. Jean M. Casner (Age 66)
    Senior VP & Chief Human Resources Officer
  • Mr. Tom Blount (Age 50)
    Senior VP & President of North America














EMBC Stock Analysis - Frequently Asked Questions

Should I buy or sell Embecta stock right now?

2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Embecta in the last year. There are currently 1 sell rating and 1 hold rating for the stock. The consensus among Wall Street research analysts is that investors should "reduce" EMBC shares.
View EMBC analyst ratings
or view top-rated stocks.

What is Embecta's stock price target for 2024?

2 Wall Street research analysts have issued 1-year price targets for Embecta's shares. Their EMBC share price targets range from $16.00 to $16.00. On average, they anticipate the company's stock price to reach $16.00 in the next twelve months. This suggests a possible upside of 9.2% from the stock's current price.
View analysts price targets for EMBC
or view top-rated stocks among Wall Street analysts.

How have EMBC shares performed in 2024?

Embecta's stock was trading at $18.93 on January 1st, 2024. Since then, EMBC shares have decreased by 22.6% and is now trading at $14.65.
View the best growth stocks for 2024 here
.

Are investors shorting Embecta?

Embecta saw a decrease in short interest during the month of January. As of January 31st, there was short interest totaling 2,380,000 shares, a decrease of 9.2% from the January 15th total of 2,620,000 shares. Based on an average trading volume of 488,900 shares, the short-interest ratio is currently 4.9 days. Approximately 4.2% of the company's stock are short sold.
View Embecta's Short Interest
.

When is Embecta's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Friday, May 10th 2024.
View our EMBC earnings forecast
.

How were Embecta's earnings last quarter?

Embecta Corp. (NASDAQ:EMBC) announced its quarterly earnings data on Friday, February, 9th. The company reported $0.61 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.46 by $0.15. The company had revenue of $277.30 million for the quarter, compared to analyst estimates of $264.92 million. Embecta had a negative trailing twelve-month return on equity of 18.66% and a net margin of 4.93%. The firm's revenue for the quarter was up .6% compared to the same quarter last year. During the same period last year, the business earned $0.93 earnings per share.

How often does Embecta pay dividends? What is the dividend yield for Embecta?

Embecta announced a quarterly dividend on Friday, February 9th. Shareholders of record on Wednesday, February 28th will be given a dividend of $0.15 per share on Friday, March 15th. This represents a $0.60 annualized dividend and a yield of 4.10%. The ex-dividend date is Tuesday, February 27th.
Read our dividend analysis for EMBC
.

Is Embecta a good dividend stock?

Embecta (NASDAQ:EMBC) pays an annual dividend of $0.60 per share and currently has a dividend yield of 4.14%. EMBC has a dividend yield higher than 75% of all dividend-paying stocks, making it a leading dividend payer. The dividend payout ratio is 63.16%. This payout ratio is at a healthy, sustainable level, below 75%. Based on earnings estimates, EMBC will have a dividend payout ratio of 27.15% next year. This indicates that the company will be able to sustain or increase its dividend.
Read our dividend analysis for EMBC.

What ETFs hold Embecta's stock?

ETFs with the largest weight of Embecta (NASDAQ:EMBC) stock in their portfolio include Invesco S&P Spin-Off ETF (CSD).Invesco S&P SmallCap Health Care ETF (PSCH).

What guidance has Embecta issued on next quarter's earnings?

Embecta issued an update on its FY 2024 earnings guidance on Friday, February, 9th. The company provided earnings per share (EPS) guidance of 1.950-2.150 for the period, compared to the consensus EPS estimate of 2.000. The company issued revenue guidance of $1.1 billion-$1.1 billion, compared to the consensus revenue estimate of $1.1 billion.

Who are Embecta's major shareholders?

Embecta's stock is owned by a number of institutional and retail investors. Top institutional shareholders include Vanguard Group Inc. (12.20%), River Road Asset Management LLC (5.75%), Yacktman Asset Management LP (4.64%), Charles Schwab Investment Management Inc. (2.24%), Balyasny Asset Management L.P. (1.49%) and Northern Trust Corp (1.16%). Insiders that own company stock include David F Melcher, Devdatt Kurdikar, Jacob Elguicze and Jeffrey Z Mann.
View institutional ownership trends
.

How do I buy shares of Embecta?

Shares of EMBC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:EMBC) was last updated on 2/21/2024 by MarketBeat.com Staff